Literature DB >> 26197883

Vagal afferent-dependent cholecystokinin modulation of visceral pain requires central amygdala NMDA-NR2B receptors in rats.

E M Wang1, W T Li1, X J Yan1, X Chen1, Q Liu1, C C Feng1, Z J Cao1, J Y Fang1, S L Chen1.   

Abstract

BACKGROUND: Cholecystokinin (CCK), a gut hormone that is released during feeding, exerts gastrointestinal effects in part through vagal pathway. It is reported to be a potential trigger for increased postprandial visceral sensitivity in healthy subjects and, especially in patients with irritable bowel syndrome. NR2B-containing N-methyl-d-aspartate (NMDA) receptors in the central amygdala (CeA) participate in pain modulation. Systemically administered CCK activates the CeA-innervating neurons. Here, we investigated whether CCK modulation of visceral sensitivity is mediated through CeA NMDA-NR2B receptors and whether this modulation involves vagal pathway.
METHODS: We first examined the visceromotor response (VMR) to colorectal distention (CRD) following i.p. injection of CCK octapeptide (CCK-8) in a rat model. Next, the NR2B antagonist ifenprodil and the NR2A antagonist NVP-AAM077 were microinjected into the CeA before systemic CCK injection. NR2B phosphorylation was detected by Western blot. To down-regulate NR2B gene expression, NR2B-specific small interfering RNA (siRNA) was delivered into CeA neurons by electroporation. In addition, the effects of functional deafferentation by perivagal application of capsaicin and pretreatment with the CCK1 receptor antagonist devazepide were investigated. KEY
RESULTS: CCK-8 increased VMR to CRD in a dose-dependent manner. This effect was blunted by intra-CeA administration of ifenprodil (but not NVP-AAM077) and was accompanied by phosphorylation of NR2B subunits in the CeA. CCK failed to increase VMR to CRD in NR2B siRNA-treated rats. Perivagal capsaicin application and pretreatment with devazepide prevented CCK-induced pronociception and CeA NR2B phosphorylation. CONCLUSIONS & INFERENCES: The pronociception induced by systemic CCK, which is vagal afferent-dependent, requires activation of CeA NMDA-NR2B receptors.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  NR2B receptors; cholecystokinin; the central amygdala; vagal afferents; visceral pain

Mesh:

Substances:

Year:  2015        PMID: 26197883     DOI: 10.1111/nmo.12633

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  6 in total

Review 1.  Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome.

Authors:  Rachel D Moloney; Anthony C Johnson; Siobhain M O'Mahony; Timothy G Dinan; Beverley Greenwood-Van Meerveld; John F Cryan
Journal:  CNS Neurosci Ther       Date:  2015-12-10       Impact factor: 5.243

Review 2.  Meal-Sensing Signaling Pathways in Functional Dyspepsia.

Authors:  Amanda J Page; Hui Li
Journal:  Front Syst Neurosci       Date:  2018-04-05

3.  Cholecystokinin type B receptor-mediated inhibition of A-type K+ channels enhances sensory neuronal excitability through the phosphatidylinositol 3-kinase and c-Src-dependent JNK pathway.

Authors:  Shumin Yu; Yuan Zhang; Xianyang Zhao; Zhigang Chang; Yuan Wei; Yufang Sun; Dongsheng Jiang; Xinghong Jiang; Jin Tao
Journal:  Cell Commun Signal       Date:  2019-06-18       Impact factor: 5.712

4.  Vagal Transient Receptor Potential Ankyrin 1 Mediates Stress-exacerbated Visceral Mechanonociception After Antral Cold Exposure.

Authors:  Xin Chen; Qingqing Luo; Xiujuan Yan; Wenting Li; Shengliang Chen
Journal:  J Neurogastroenterol Motil       Date:  2019-07-01       Impact factor: 4.924

5.  Vagal gut-brain signaling mediates amygdaloid plasticity, affect, and pain in a functional dyspepsia model.

Authors:  Zachary A Cordner; Qian Li; Liansheng Liu; Kellie L Tamashiro; Aditi Bhargava; Timothy H Moran; Pankaj Jay Pasricha
Journal:  JCI Insight       Date:  2021-03-22

6.  Leptin Contributes to Neuropathic Pain via Extrasynaptic NMDAR-nNOS Activation.

Authors:  Yanling Liang; Yuxin Ma; Jieqin Wang; Lei Nie; Xusheng Hou; Wenyu Wu; Xingmei Zhang; Yinghong Tian
Journal:  Mol Neurobiol       Date:  2020-10-25       Impact factor: 5.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.